Verification of a decision analytic model assumption using real-world practice data: Implications for the cost effectiveness of Cyclo-oxygenase 2 inhibitors (COX-2s)

American Journal of Managed Care

Volumn 9, Issue 12, 2003, Pages 785-794

  Cox, Emily R ^a   Motheral, Brenda ^a   Mager, Doug ^a  

^a Express Scripts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIINFECTIVE AGENT; BISMUTH; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; GENERIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SUCRALFATE;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE SEVERITY; DRUG COST; DRUG SELECTIVITY; DRUG USE; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEALTH INSURANCE; HEARTBURN; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; OSTEOARTHRITIS; OUTCOMES RESEARCH; PAIN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STOMACH PAIN; STOMACH ULCER; UNITED STATES; VALIDATION PROCESS; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE INHIBITORS; DECISION SUPPORT TECHNIQUES; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; MIDWESTERN UNITED STATES; MODELS, ECONOMETRIC; OSTEOARTHRITIS; PREFERRED PROVIDER ORGANIZATIONS;

EID: 0347915806     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mullins CD, Wang J. Pharmacy benefit management: Enhancing the applicability of pharmacoeconomics for optimal decision making. PharmacoEconomics. 2002;20:9-21.
2. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: Practical applications and methodological shortcomings. PharmacoEconomics. 1997;12:121-129.
3. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum. 1995;38:1535-1540.
4. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541-1546.
5. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998;93:2037-2046.
6. McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol. 2001;15:755-773.
7. Lapane KL, Spooner JJ, Pettitt D. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis. Am J Manag Care. 2001;7:402-408.
8. Simon LS, Zhao SZ, Arguelles LM, et al. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. Clin Ther. 1998;20:1218-1235.
9. Singh G. Recent considerations in non-steroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105:31S-38S.
10. Haglund U, Svarvar P. The Swedish ACCES model: Predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology. 2000;39(suppl 2):51-56.
11. Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. PharmacoEconomics. 2001;19(suppl 1):49-58.
12. Svarvar P, Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology. 2000;39(suppl 2):43-50.
13. Chancellor JVM, Hunsche E, De Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. PharmacoEconomics. 2001;19(suppl 1):59-75.
14. Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther. 2001;23:1061-1079.
15. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. PharmacoEconomics. 2001;19:1039-1049.
16. Moore RA, Phillips CJ, Pellissier JM, Kong SX. Health economic comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ. 2001;4:1-17.
17. Pettitt D, Goldstein JL, McGuire A, Schwartz JS, Burke T, Maniadakis N. Overview of the arthritis cost consequence evaluation system (ACCES): A pharmacoeconomic model for celecoxib. Rheumatology. 2000;39(suppl 2):33-42.
18. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624-629.
19. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt DJ. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 agents: Quantitative assessment of channeling bias and confounding by indication in 6689 RA and OA patients. J Rheumatol. 2002;29:1015-1022.
20. Singh G, Terry R, Ramey DR, Triadafilopoulus G, Brown BW. GI SCORE: A simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications. Arthritis Rheum. 1997;40(suppl):S93.
21. Bull SA, Conell C, Campen DH. Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. J Manag Care Pharm. 2002;8:252-258.
22. Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: A decision analysis. Arthritis Care Res. 2002;47:36-43.
23. Motheral BR, Fairman KA. The use of claims databases for outcomes research: Rationale, challenges, and strategies. Clin Ther. 1997;19:346-366.
24. Tamblyn R, Lavoei G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995;48:999-1009.
25. Kirking DM, Ammann MA, Harrington CA. Comparison of medical records and prescription claims files in documenting prescription medication therapy. J Pharmacoepi. 1996;5(1):3.
26. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA. 2000;284:1247-1255.
27. Bombadier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
28. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-1933.
29. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation and pharmacoeconomic analyses: A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283:2116-2121.
30. Rennie D, Luft HS. Pharmacoeconomic analyses: Making them transparent, making them credible. JAMA. 2000;283:2158-2160.
31. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. PharmacoEconomics. 2000;17:501-513.
32. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses [editorial]. N Engl J Med. 1994;331:669-670.
33. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: Uses, roles, and validity. Value Health. 2001;4:348-361.